FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3085704927> ?p ?o ?g. }

• W3085704927 abstract "Abstract Purpose The purpose of this study was to evaluate whether the dose to bladder neck (BN) is a predictor of acute and late urinary toxicity after high-dose-rate brachytherapy (HDRB) boost for prostate cancer. Methods and Materials Between 2014 and 2016, patients with prostate cancer treated at our institution with external beam radiation therapy and 15 Gy single-fraction HDRB boost for intermediate- and high-risk disease according to D'Amico definition were reviewed. Intraoperative CT scan–based inverse planning and ultrasound-based inverse planning were performed in 173 and 136 patients, respectively. The following structures were prospectively contoured: prostate, urethra, rectum, bladder, and the BN defined as 5 mm around the urethra between the catheter balloon and the prostatic urethra. Dose to the BN was reported only, no constraint was applied. Acute and late urinary toxicity were assessed using the International Prostate Symptom Score (IPSS) and the Common Terminology Criteria for Adverse Events v.4.0. Clinical and dosimetry factors associated with urinary toxicity were analyzed using generalized linear models. Results A total of 309 patients with median age of 71 years (range 50–89) were included. Median followup was 25 months (range 0–39 months). Using D'Amico definition, 71% of the patients had intermediate-risk disease, whereas 29% had high-risk disease. The mean pretreatment prostate-specific antigen value was 9.65 ng/mL. The mean pretreatment, after 6 weeks and over 6 months IPSSs were 8.34, 12.14, and 10.02, respectively. Urinary obstruction was reported in 14 cases (4.5%). Pretreatment IPSS (p = 0.003) and prostate volume (p = 0.024) were significantly associated with acute and late urinary toxicity. The dose for the most exposed 2 cc (D2cc) of BN was not correlated with acute (p = 0.798) or late urinary toxicity (p = 0.859). BN D2cc was not correlated with urinary obstruction (p = 0.272), but bladder V75 was (p = 0.021). Conclusions High pretreatment IPSS, large prostate volume and bladder V75 were the only predictors of acute and late urinary toxicity after HDRB boost in our study. Although BN D2cc was associated with acute and late urinary toxicity after low-dose-rate brachytherapy, no correlation was found after HDRB. A prospective study comparing dose to the BN in HDRB monotherapy would validate the impact of BN dose on acute and late urinary toxicity." @default.
• W3085704927 created "2020-09-21" @default.
• W3085704927 creator A5001173113 @default.
• W3085704927 creator A5002554248 @default.
• W3085704927 creator A5010341407 @default.
• W3085704927 creator A5015716448 @default.
• W3085704927 creator A5025035225 @default.
• W3085704927 creator A5037727718 @default.
• W3085704927 creator A5046424007 @default.
• W3085704927 creator A5049072127 @default.
• W3085704927 creator A5062370609 @default.
• W3085704927 creator A5065763418 @default.
• W3085704927 creator A5085305869 @default.
• W3085704927 date "2020-09-01" @default.
• W3085704927 modified "2023-10-10" @default.
• W3085704927 title "Dose to the bladder neck is not correlated with urinary toxicity in patients with prostate cancer treated with HDR brachytherapy boost" @default.
• W3085704927 cites W1012954095 @default.
• W3085704927 cites W1964735557 @default.
• W3085704927 cites W1973393748 @default.
• W3085704927 cites W1977970364 @default.
• W3085704927 cites W1986031929 @default.
• W3085704927 cites W1995761318 @default.
• W3085704927 cites W1998201907 @default.
• W3085704927 cites W2054899405 @default.
• W3085704927 cites W2062313368 @default.
• W3085704927 cites W2082179683 @default.
• W3085704927 cites W2085309775 @default.
• W3085704927 cites W2085471307 @default.
• W3085704927 cites W2128760486 @default.
• W3085704927 cites W2553678345 @default.
• W3085704927 cites W2569728867 @default.
• W3085704927 cites W2586272675 @default.
• W3085704927 cites W2602775013 @default.
• W3085704927 cites W2629781268 @default.
• W3085704927 cites W2716892249 @default.
• W3085704927 cites W2810962735 @default.
• W3085704927 cites W2883446656 @default.
• W3085704927 cites W2945855863 @default.
• W3085704927 cites W2963925928 @default.
• W3085704927 doi "https://doi.org/10.1016/j.brachy.2020.06.017" @default.
• W3085704927 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32928485" @default.
• W3085704927 hasPublicationYear "2020" @default.
• W3085704927 type Work @default.
• W3085704927 sameAs 3085704927 @default.
• W3085704927 citedByCount "2" @default.
• W3085704927 countsByYear W30857049272021 @default.
• W3085704927 countsByYear W30857049272023 @default.
• W3085704927 crossrefType "journal-article" @default.
• W3085704927 hasAuthorship W3085704927A5001173113 @default.
• W3085704927 hasAuthorship W3085704927A5002554248 @default.
• W3085704927 hasAuthorship W3085704927A5010341407 @default.
• W3085704927 hasAuthorship W3085704927A5015716448 @default.
• W3085704927 hasAuthorship W3085704927A5025035225 @default.
• W3085704927 hasAuthorship W3085704927A5037727718 @default.
• W3085704927 hasAuthorship W3085704927A5046424007 @default.
• W3085704927 hasAuthorship W3085704927A5049072127 @default.
• W3085704927 hasAuthorship W3085704927A5062370609 @default.
• W3085704927 hasAuthorship W3085704927A5065763418 @default.
• W3085704927 hasAuthorship W3085704927A5085305869 @default.
• W3085704927 hasConcept C121608353 @default.
• W3085704927 hasConcept C122732770 @default.
• W3085704927 hasConcept C126322002 @default.
• W3085704927 hasConcept C126838900 @default.
• W3085704927 hasConcept C126894567 @default.
• W3085704927 hasConcept C141071460 @default.
• W3085704927 hasConcept C2776235491 @default.
• W3085704927 hasConcept C2777085111 @default.
• W3085704927 hasConcept C2777416452 @default.
• W3085704927 hasConcept C2777793932 @default.
• W3085704927 hasConcept C2779762690 @default.
• W3085704927 hasConcept C2780192828 @default.
• W3085704927 hasConcept C2781074409 @default.
• W3085704927 hasConcept C509974204 @default.
• W3085704927 hasConcept C71924100 @default.
• W3085704927 hasConcept C77411442 @default.
• W3085704927 hasConceptScore W3085704927C121608353 @default.
• W3085704927 hasConceptScore W3085704927C122732770 @default.
• W3085704927 hasConceptScore W3085704927C126322002 @default.
• W3085704927 hasConceptScore W3085704927C126838900 @default.
• W3085704927 hasConceptScore W3085704927C126894567 @default.
• W3085704927 hasConceptScore W3085704927C141071460 @default.
• W3085704927 hasConceptScore W3085704927C2776235491 @default.
• W3085704927 hasConceptScore W3085704927C2777085111 @default.
• W3085704927 hasConceptScore W3085704927C2777416452 @default.
• W3085704927 hasConceptScore W3085704927C2777793932 @default.
• W3085704927 hasConceptScore W3085704927C2779762690 @default.
• W3085704927 hasConceptScore W3085704927C2780192828 @default.
• W3085704927 hasConceptScore W3085704927C2781074409 @default.
• W3085704927 hasConceptScore W3085704927C509974204 @default.
• W3085704927 hasConceptScore W3085704927C71924100 @default.
• W3085704927 hasConceptScore W3085704927C77411442 @default.
• W3085704927 hasLocation W30857049271 @default.
• W3085704927 hasOpenAccess W3085704927 @default.
• W3085704927 hasPrimaryLocation W30857049271 @default.
• W3085704927 hasRelatedWork W10516468 @default.
• W3085704927 hasRelatedWork W11918868 @default.
• W3085704927 hasRelatedWork W14767499 @default.
• W3085704927 hasRelatedWork W15032023 @default.
• W3085704927 hasRelatedWork W15050538 @default.
• W3085704927 hasRelatedWork W19777685 @default.

• next